General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphoma-
Latest Information Update: 08 Jan 2022
At a glance
- Drugs Polatuzumab vedotin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 24 May 2021 New trial record